118 results about "Pox virus" patented technology

The invention relates to the technical field of medicines, in particular to application of salinomycin in preparation of oral medicines for preventing or treating monkey pox virus (MPXV) infection. Salinomycin is a polyether antibiotic produced by actinomycetes. It is found for the first time that salinomycin can efficiently inhibit monkey pox virus infection on the cell culture level, and can significantly improve the survival rate of mice infected with monkey pox virus in small animal living bodies. More importantly, salinomycin can be administered by oral administration, has good bioavailability and safety, and provides a brand new treatment means for monkey pox virus infection. The medicinal value of salinomycin in resistance to monkey pox virus infection is reported for the first time at home and abroad, and the application prospect of salinomycin in the field of viral disease treatment is expanded.

This invention relates to monoclonal antibodies for detecting A35R protein and their applications. This invention screened six antibodies, including antibody 4E7, antibody 11G12, antibody 6F10, antibody 6C11, antibody 18C3, and antibody 23A7. Specifically, this invention discloses the amino acid sequences of the heavy chain variable region and the light chain variable region of the above antibodies, as well as the amino acid sequences of their complementarity-determining regions and framework regions. Antibodies 4E7 and 11G12 can bind not only to the A35R-MPXV protein but also to its homologs A35R-CPXV, A35R-VTT8, and A35R-Variola. Antibodies 6F10, 6C11, 23A7, and 18C3 can specifically recognize the A35R-MPXV protein. The monoclonal antibodies described above all exhibit high binding capacity to the A35R protein, making them suitable for the sensitive and specific detection and prevention of monkeypox virus A35R protein. They can also be used clinically for the diagnosis and treatment of monkeypox virus infection-related diseases.

The present invention relates to 2'-fluoro-6'-methylene carbocyclic nucleosides and nucleotides, pharmaceutical compositions containing these nucleosides and nucleotides, and their use in the treatment or prophylaxis of poxvirus infections and secondary disease states and conditions thereof.

Provided herein are methods of producing immunoglobulin Y (IgY) antibodies against monkeypox virus. The method includes immunizing hens with a peptide encoding at least one immunogenic domain of A29 fusion protein from the monkeypox virus and isolating the IgY antibodies against the A29 fusion protein from yolks of eggs laid by the immunized hens. Pharmaceutical compositions containing the IgY antibodies and methods of inhibiting or treating monkeypox virus infection are also provided.

This application discloses antibodies against monkeypox virus, their preparation methods, and applications. Specifically, this application discloses eight antibodies (A35R-9E4, A35R-9F8, A35R-10C4, A35R-10D5, A35R-10E7, A35R-10H6, A35R-18E2, and A35R-18H2) that have excellent affinity for the monkeypox virus A35R protein, and that they exhibit good neutralizing activity and certain in vivo protective effects.

Provided are a primer-probe combination for real-time quantitative PCR, a related kit, and a method for using primers to measure the titers of measles, mumps and varicella virus pathogens. The method is applicable to clinical and laboratory detection, is fast and convenient, and has high sensitivity.

The present disclosure relates to smallpox vaccines and stem cells for treating diseases. Described herein are methods and compositions for treating an inflammatory disease or an infectious disease in a subject in need thereof by administering a poxvirus and a stem cell to the subject, wherein the disease is not a cancer. For example, the disease can be a chronic inflammatory disease (e.g., an autoimmune disease).

The application belongs to the technical field of image recognition, and discloses a monkeypox virus classification method and system based on image comparison and a storage medium, which comprises an individual reference modeling module, collects normal skin and initial lesion images of a healthy side of a patient, generates a healthy texture template and an initial lesion reference library, performs gray scale normalization on the healthy texture template and the initial lesion reference library through adaptive histogram stretching, and outputs a comparison reference image group; a symptom density quantification module, acquires a current monitoring image of the patient, segments a lesion area in combination with the comparison reference image group, extracts layered features of the lesion area to generate a three-dimensional symptom density vector, extracts texture roughness of a surface of the lesion area, and constitutes a lesion quantification data set; the accuracy of disease monitoring is improved, and a clinical nursing process is optimized.

The present application relates to a kind of artificially synthesized recombinant monoclonal antibody with human antibody amino acid sequence as framework.The present application uses phage display technology, and obtains one monoclonal antibody H11 from Tomlinson I+J phage library, and these new amino acid sequences constitute CDR1, CDR2 and CDR3 region, can be combined with A29L protein specific binding.It shows good stability, high specificity and high affinity and other characteristics, provide tool support for subsequent monkeypox virus diagnosis and detection with A29L protein as target.

The invention relates to the field of antibody engineering, in particular to a monoclonal antibody specifically targeting a monkey pox virus and application of the monoclonal antibody. According to the invention, by screening mouse memory B cells specifically combined with monkey pox virus envelope protein A35R, monkey pox virus antibodies 1H4, 3H3, 3H6, 13H1 and 17H1 with high neutralization activity are obtained. Wherein 17H1 has excellent affinity and neutralizing efficacy on monkey pox virus and has a strong in-vivo protection effect, and 100% of survival rate of challenged mice is achieved in prevention and treatment experiments. The sequence of the antibody is completely different from that of an existing monkey pox virus antibody, and a new candidate product is provided for detection, diagnosis, prevention and treatment of the monkey pox virus.

Disclosed are an assay, method, and kit for detecting a monkeypox virus (MPXV) and the application thereof. The assay may be used alone or in combination with another assay or assays. The method of using and kit includes a composition used for detecting MPXV, wherein the composition is composed of a primer pair and a probe. The primer pair is composed of two single-stranded nucleic acid molecules shown in the first sequence and the second sequence in a sequence list, and the sequence of the probe is the third sequence in the sequence list. The kit is used for detecting MPXV, and has advantages of providing real-time screening of MPXV reducing cross-reaction to other pox diseases, and increasing specificity to MPXV for disease prevention and improvement of public health.

The present invention is related to method of preparing a gain-of-function mutation in poxvirus, like buffalopox virus (BPXV) by long-term propagating it in the presence of methyltransferase inhibitor like 3-Deazaneplanocin A (DZNep), which results in generation of viral 2'O-MTAse (VP39) mutant with a single point mutation (M236I). The resultant mutant has the following characteristics: (a) M236I mutation of 2'O-MTAse increases the cap-1 markings on viral mRNA; (b) The 2'O-MTAse mutant virus had hyperactive 2'O-MTAse and exhibited enhanced stability and translational efficiency of its mRNA; (c) The capping (cap1) performed by the mutant viral 2'O-MTAse (VP39) results in higher viral protein production, as compared to the wild type VP39 and (d) Mutant virus replicated at higher viral titer than the wild-type virus.

The present application relates to the technical field of biotechnology, in particular to a monoclonal antibody against A29L protein of monkeypox virus and application thereof. The present application prepares the monoclonal antibody against A29L protein of monkeypox virus, and through optimization of antibody screening and expression technology, the antibody with high affinity and high specificity is screened, and then a new tool is provided for rapid detection, effective neutralization and treatment of monkeypox virus, and an important immunological basis is provided for vaccine research and development and treatment scheme design of monkeypox virus.

This invention discloses a high-throughput screening method for monkeypox virus (MPXV) N7-methyltransferase (N7-MTase) inhibitors based on fluorescence polarization technology and its application. This method uses MPXV E1... CTD Using the / E12 protein complex as a target, and leveraging the specific binding characteristic of the fluorescent probe FL-NAH to the target catalytic center, small molecule inhibitors that competitively bind to the SAM binding site are screened by monitoring changes in fluorescence polarization signals. This invention yielded a series of candidate compounds with significant inhibitory activity. Experiments demonstrated that these inhibitors exhibit strong inhibitory effects on MPXV N7-MTase, with a biochemical IC50 level of [missing information]. 50 Preferably, the concentration can reach 4.65 μM; at the cellular level, the compound exhibits a clear attenuation effect against poxviruses, with an EC50 value of [missing value]. 50 The range is up to 46.75 μM, and it has low cytotoxicity (CC). 50 >200 μM).

The present invention is directed to a method for detecting the presence or absence of monkeypox virus (MPXV) in a biological sample, the method comprising: a) contacting the sample or nucleic acid extracted from said sample with reagents and an oligonucleotide combination capable of amplifying a target region of a monkeypox viral genome, wherein said oligonucleotide combination is selected from the group consisting of: i) a B7R oligonucleotide primer set specific for amplifying a target sequence in the B7R gene of the MPXV genome generating an MPXV amplification product comprising the sequence of SEQ ID NO:65; and ii) a G2R oligonucleotide primer set specific for amplifying a target sequence in the G2R gene of the MPXV genome generating an MPXV amplification product comprising the sequence of SEQ ID NO:63; b) performing an in vitro nucleic acid amplification reaction, wherein any MPXV nucleic acid present in the sample is used as a template to generate the MPXV amplification product corresponding to the oligonucleotide combination of i) or ii); and c) detecting the presence or absence of the MPXV amplification product generated in step b), wherein the presence of the MPXV amplification product is indicative of the presence of MPXV in the biological sample. The present invention also provides oligonucleotides which can be used in the method of the invention as primers and probes.

The application belongs to the technical field of virus detection, and discloses a sheep disease virus multiplex PCR detection primer, method and application. The base sequence of the primer FMDV-F of the sheep foot-and-mouth disease virus is SEQ ID NO:1, the base sequence of the primer FMDV-R is SEQ ID NO:2; the base sequence of the primer ORFV-F of the sheep orf virus is SEQ ID NO:3, the base sequence of the primer ORFV-R is SEQ ID NO:4; the base sequence of the primer GTPV-F of the goat pox virus is SEQ ID NO:5, and the base sequence of the primer GTPV-R is SEQ ID NO:6. The application optimizes the multiplex PCR, determines the optimal reaction system and the optimal reaction procedure, and can accurately detect single or mixed infection of the sheep foot-and-mouth disease virus, the sheep orf virus and the goat pox virus, and has an important role in epidemiological investigation and epidemic disease prevention and control.

The application provides a monkeypox virus typing kit, application and product in situ, and belongs to the technical field of molecular detection. The application first provides a monkeypox virus typing kit in situ, which comprises primer probe compositions for identifying monkeypox branch Ia type, branch Ib type and branch II type. The application further provides a combined kit comprising monkeypox identification primer probes or orthopoxvirus identification primer probes. The application achieves the effect of balanced amplification in the same amplification system through the combination optimization of the primer probes, accurately types the monkeypox virus at one time, and simultaneously realizes the identification of the monkeypox virus or the orthopoxvirus. The kit has the characteristics of high sensitivity and high accuracy, can reduce the interference of external substances, has strong stability, and has high practical application value.

The present invention is in the field of viral immunotherapy. The invention provides 1) an efficient recombinant poxvirus expressing a toxic conditional gene product that affects the viability of the recombinant poxvirus itself if left unregulated, or 2) a recombinant poxvirus expressing a conditional gene product with an improved safety profile, a method of producing them, a composition comprising them and therapeutic uses related thereto.

A disclosed lanthanide fluorescent antigen kit based on monkey pox virus detection comprises an antigen kit, the interior of the antigen kit is fixedly connected with a fixed placing frame, the top of the fixed placing frame is provided with two concave grooves, and each concave groove is internally provided with a plurality of antigen reagent sampling mechanisms; a clamping mechanism is arranged at a position opposite to the bottom end of the antigen reagent sampling mechanism; and an ejection mechanism is arranged at the bottom end of the clamping mechanism, the clamping mechanism comprises a clamping round frame fixedly connected with the bottom end of the interior of the concave groove, and a plurality of fixed rectangular shells are arranged at the top end of the interior of the clamping round frame. According to the scheme, a lanthanide fluorescent antigen reagent test tube for detecting the monkey pox virus is conveniently placed in a clamping round frame on the fluorescent antigen kit, and the lanthanide fluorescent antigen reagent test tube for detecting the monkey pox virus is extruded and clamped by a movable extrusion roller through telescopic matching of rectangular strips in a plurality of fixed rectangular shells.

The invention provides a method for creating a transgenic papaya strain with high papaya ringspot virus and malformed mosaic virus resistance, which comprises the following steps: respectively placing CP fusion gene segment expression cassettes of PRSV and PLDMV of papaya and selection marker gene expression cassettes into two independent T-DNA structural domains, and inserting plant expression vectors into the T-DNA structural domains; then introducing the vector into papaya to obtain a papaya strain without a selection marker; or the CP fusion gene segment expression cassettes of the PRSV and the PLDMV and the reverse sequence of the expression cassettes are connected in series and inserted into a plant expression vector, and then the vector is introduced into the papaya, so that the papaya strain with the CP fusion gene segment expression cassettes in reverse series connection is obtained. The papaya without the selection marker does not contain the selection marker, so that the safety can be effectively improved; the papaya in which the CP fusion gene segment expression cassettes are reversely connected in series does not need to be further homozygous to enhance the disease-resistant effect.

The addition of a tyrosine kinase inhibitor, including but not limited to imatinib, in a dosage regimen in combination with tecovirimat provides superior results in the treatment of orthopox infections, including monkeypox infections or monkeypox disease. The unexpected results show that the combined administration of imatinib and tecovirimat provides synergistic reduction of monkeypox spread.

The application discloses primers and fluorescent probes for detection of monkeypox virus. The nucleic acid sequence of the primers comprises sequences shown in SEQ ID NO. 1-SEQ ID NO. 4; and the nucleic acid sequence of the fluorescent probes comprises sequences shown in SEQ ID NO. 5-SEQ ID NO. 6. Two pairs of primers and corresponding fluorescent probes are designed creatively, which can specifically detect a new target gene B21R in the monkeypox virus DNA, and the target site has conservation and specificity. In addition, a double fluorescent PCR method is established, which can further improve the specificity and accuracy of the monkeypox virus detection.

The present disclosure relates generally to vaccines against orthopoxviruses, and methods for making and using such vaccines. In particular, in some embodiments, the present disclosure relates to nanoparticle-derived vaccines, and compositions based thereon, that elicit an immune response against an orthopoxvirus. The present disclosure further relates to the use of vaccines and vaccine compositions for preventing; decreasing the severity, morbidity and / or mortality of; shortening the duration of; and / or reducing the symptoms of, a poxvirus infection, such as, for example, an orthopoxvirus infection.

This application relates to humanized monoclonal antibodies against monkeypox virus and their applications. By screening humanized mouse anti-B6R specific binding memory B cells with fully human antibodies, humanized high-neutralizing activity monkeypox virus antibodies B6R-16A1, B6R-21G7, B6R-22D12, B6R-22F9, and B6R-22H1 were obtained. These antibodies have the characteristics of strong binding ability to monkeypox virus, good in vitro neutralization, high affinity, and in vivo protective effect.

The application discloses a 4-quinolinone derivative, a preparation method and application thereof. The compound has a structure shown in general formula I. The application further relates to a pharmaceutical composition containing the compound with the structure of formula I. Activity screening experiments show that the compound has good anti-positive poxvirus activity, and therefore the application further provides application of the compound in preparation of an anti-positive poxvirus drug.

This invention discloses a primer-probe combination for detecting monkeypox virus and its branches, and its application, belonging to the field of virus detection technology. Based on the monkeypox virus genome, this invention successfully designed a set of specific primers and probes capable of detecting monkeypox virus and its branches. Based on these primers and probes, this invention establishes a method for detecting monkeypox virus and its branches using multiplex real-time fluorescent PCR. This method can accurately detect the pathogen in clinical monkeypox virus samples, and the detection results are completely consistent with the typing results determined by genome sequencing. The detection method provided by this invention is low-cost, effectively reduces labor and time costs, and improves detection efficiency, showing promising application prospects in laboratory diagnosis, on-site detection, and health assessment of viruses.

The invention discloses a monoclonal antibody MPXV-mAb 975 and an application of the monoclonal antibody MPXV-mAb 981 in preparation of a medicine for preventing and treating a monkey pox virus. According to the invention, an established plaque phenotype experiment is utilized to evaluate the neutralizing activity of the two antibodies to the VACV, and the result shows that the two monoclonal antibodies can inhibit the propagation of the VACV between cells; effects of ADCC and ADCP mediated by the two antibodies are detected, and through a reporter gene experiment, the two antibodies show potential ADCC and ADCP activity; animal model data shows that both the two antibodies can protect CAST / EiJ mice and rhesus monkeys, monkey pox virus loads in different tissues and organs of the mice are remarkably reduced, and the number of acnes on the skin of the rhesus monkeys is reduced. The invention proves that the two monoclonal antibodies have in-vivo and in-vitro protection effects, can be used as effective prevention and treatment medicines for monkey pox virus infection, and provide candidate antibody preparations for clinical treatment of monkey pox virus infection.

The invention belongs to the field of biological medicine, and particularly relates to application of Thaflavanin-3 '-Gallate or NAD < + > in preparation of a product for preventing or treating monkey pox virus infection. The invention finds that the protein OPG188 of the monkey pox virus can significantly inhibit the natural immune process of the monkey pox virus, compounds Thaflavanin-3 '-Gallate and NAD + which have the highest affinity with the OPG188 are screened out through molecular virtual docking, and the action effects of the compounds are verified through cell experiments and molecular experiments, which indicates that the Thaflavanin-3'-Gallate and NAD + have the effect of inhibiting the replication of the monkey pox virus. The compound can be used for preparing medicines for resisting monkey pox virus infection.

The present application relates to monkeypox virus human monoclonal antibody and its application, through screening human antibody humanization mouse anti A29L specific binding memory B cell, the human source high neutralization activity monkeypox virus antibody A29L-1B3, A29L-1B2, A29L-1A5 and A29L-1A2 obtained, have the characteristics such as strong monkeypox virus binding ability, good in-vitro neutralization, affinity, have in-vivo protective effect, and are completely different from the monkeypox virus antibody sequence reported, provide the product for the detection and neutralization of monkeypox virus, and provide the possibility for providing the monkeypox virus product with in-vivo protective effect.

Based on a monkey pox virus immunodiagnosis technology based on up-conversion and long-afterglow nanoparticles, the preparation method comprises the following steps: preparing the long-afterglow and up-conversion nanoparticles by adopting a hydrothermal method and a solvothermal method respectively, and constructing the antibody-modified UCNP and PLNP nano probe by utilizing an EDC-NHS cross-linking system after carboxylation modification. The two nanoprobes and an antigen form an immune complex in a double antibody sandwich mode, the UCNPs is excited to emit light at the wavelength of 980 nm, the UCNPs and the PLNPs generate an LRET effect, an obvious signal peak is detected at the wavelength of 700 nm, and the fluorescence signal intensity is in direct proportion to the antigen content. The detection technology is portable and high in sensitivity, the detection limit is as low as the pg / ml level, and the monkey pox virus antigen standard substance can be detected in the range of 1 mg / ml to 1 ng / ml. According to the immunodetection technology provided by the invention, the detection of various pathogens can be realized by replacing antibody combinations aiming at different antigen epitopes, and the application potential in the aspect of infectious disease diagnosis is huge.